Evaluation Of Drug Benefits Needs Quantitative Measures, FDA's Graham Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Evidence-based standards currently applied to risk should be applied to benefit, the FDAer adds.
You may also be interested in...
Drug Risks And Benefits Should Be Quantified For Public, Pfizer Exec Says
Industry will collaborate with FDA on ways to communicate risk/benefit information to patients, physicians and lawmakers, Pfizer Senior VP Corr says.
Serevent, Advair, Foradil Withdrawals To Be Considered By Advisory Committee
FDA's Pulmonary-Allergy Drugs Advisory Committee will vote July 13 whether currently available data support continued marketing of the long-acting beta-agonist bronchodilators. Committee will also consider labeling changes for formoterol concerning severe asthma exacerbations.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter